



Contacts: Dr. Amit Kumar
Tel. (425) 493-2200
Fax. (425) 493-2010

FOR RELEASE
March 14, 2007

**COMBIMATRIX MOLECULAR DIAGNOSTICS LAUNCHES HEMESCAN™
PROGNOSTIC FOR THE MANAGEMENT OF CHRONIC LYMPHOCYTIC
LEUKEMIA**

Newport Beach, Calif. – (BUSINESS WIRE) – March 14, 2007 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation of the first of its HemeScan™ suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests. The test is designed to detect prognostic markers in chronic lymphocytic leukemia (CLL) and is now available to the clinical community through both routine clinical sample processing as well as through CMDX's innovative Technical Only Program for reference laboratories. This array is the industry's first clinically validated cancer diagnostic based on BAC array CGH.

CLL is the most common adult leukemia in the western hemisphere. There are approximately 10,000 new cases diagnosed in the U.S. each year with approximately 150,000 patients living with the disease at any given time. Patients diagnosed with CLL exhibit highly variable clinical courses, with some progressing rapidly to aggressive disease and death, while others exhibit an indolent state throughout a major portion of their normal life expectancy. Hence, the concept of prognosis at diagnosis is particularly relevant in CLL. Recent studies have shown a direct correlation between specific genomic imbalances and disease course. For example, CLL patients who have a deletion of 17p involving the p53 tumor suppressor gene typically progress to aggressive disease and death in a matter of months. Other patients exhibiting the same symptoms, but with duplication of chromosome 12 or deletion of 13q14, can live for a dozen years before their disease progresses. Similarly, other genomic aberrations have an impact on clinical course, and knowledge of these enables a personalized course of treatment.

HemeScan is designed to identify all of the known prognostic genomic imbalances relevant to the clinical course of CLL. By replacing the time-consuming and often subjective manual enumeration of several Fluorescent In Situ Hybridization (FISH) probe signals,

HemeScan offers an innovative approach to prognosis at diagnosis, and hence better disease management.

“Our HemeScan for CLL Prognostic markers is the first CMDX oncology product from our HemeScan suite and is expected to be followed by additional hematology/oncology tests shortly,” said Dr. Shelly Gunn, Medical Director of CombiMatrix Molecular Diagnostics. “Our entry into the cancer-prognostic arena comes on the heels of intense research and further highlights the powerful strategic value of our partnership with the world-renowned Centre for Applied Genomics in Toronto.”

According to Gabriel Khodr, Medical Director of Southwest Genetics, San Antonio’s largest private genetics laboratory, “By virtue of its recent product introductions, CMDX is establishing itself as a premier molecular-diagnostic company. It is exciting to see microarray products mature to a point where they can have significant impact on ill patients. We have been offering CMDX’s CA650 test for several months and are now going to offer HemeScan to our clients. We feel that array-based tests are transforming genomic evaluation and management of patients and that CMDX’s ability to rapidly introduce new products is exciting and ground breaking.”

According to Dr. Joel Chan, Medical Director of Pathology Inc., a leading provider of pathology testing services in Southern California, “We have collaborated with CMDX for the clinical validation of its HemeScan and we are very pleased with the performance and robustness of the test. We look forward to incorporating this transformative test into our clinical test menu through CMDX’s innovative Technical Only Program (TOP).”

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 63 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, resource scheduling, spreadsheet automation, and user activated Internet advertising.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.